CAS 920022-47-5

RO 5028442

Description:

RO 5028442, with the CAS number 920022-47-5, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is classified as a selective inhibitor of certain enzymes, which may play a role in various biological pathways. The compound is characterized by its specific molecular structure, which includes functional groups that contribute to its biological activity and solubility properties. Typically, such compounds are evaluated for their efficacy, safety, and pharmacokinetic profiles in preclinical and clinical studies. The characteristics of RO 5028442 may include its stability under various conditions, its interaction with biological targets, and its potential side effects. As with many investigational drugs, detailed information about its mechanism of action, dosage, and therapeutic uses is often subject to ongoing research and may evolve as new data becomes available. Therefore, it is essential to consult scientific literature and databases for the most current and comprehensive information regarding this compound.

Formula: C₂₅H₂₈ClN₃O₂

Synonyms:

• Methanone, [6-chloro-1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]spiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl-
• RO-5028442; RO 5028442; RO5028442
• RO 5028442
• RO5028442, >98%
• RG7713

[6-Chloro-1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]spiro[isobenzofuran-1(3H),4′-piperidin]-1′-ylmethanone

CAS: 920022-47-5

Formula: C₂₅H₂₈ClN₃O₂

Purity: 98%

Molecular weight: 437.9617

Ref: IN-DA01DUAA

RG7713

CAS: 920022-47-5

RG7713 (RO 5028442) has been used in trials studying Autistic Disorder.

Formula: C₂₅H₂₈ClN₃O₂

Purity: 99.74%

Color and Shape: Solid

Molecular weight: 437.96

Ref: TM-T4141

RG7713

Controlled Product

CAS: 920022-47-5

RG7713 is an investigational drug that belongs to the class of cytochrome P450 3A4 (CYP3A4) inhibitors. RG7713 inhibits CYP3A4 activity and has been shown to be a potent inhibitor of CYP3A4-mediated metabolism in vitro. It is also a potent inhibitor of the human recombinant CYP3A4 enzyme, inhibiting the metabolic conversion of many drugs, including neuroleptics, antidepressants, antipsychotics, anticonvulsants, beta-blockers, and calcium channel blockers. RG7713 has demonstrated efficacy in preclinical studies in mice and rats for its cognition-enhancing effects. The drug was well tolerated at doses up to 10 mg/kg/day for 28 days without any adverse effects on body weight or food intake. There are no clinical studies yet on RG7713's safety and efficacy for humans.

Formula: C₂₅H₂₈ClN₃O₂

Purity: Min. 95%

Molecular weight: 437.96 g/mol

Ref: 3D-VLB02247